UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

~~May~~June 1425, 2025

Date of Report (Date of earliest event reported)

ARS Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39756	81-1489190
(State or other jurisdictionof incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11682 El Camino Real, Suite 120San Diego, California		92130
11682 El Camino Real, Suite 120 San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 771-9307

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~TradingSymbol~~Trading Symbol(s)		Name of each ~~exchangeon~~exchange on which registered
Common Stock, $0.0001 par value per share		SPRY		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–-2 of the Securities Exchange Act of 1934 (§ 240.12b–-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.0207 ~~Results~~Submission of ~~Operations~~Matters ~~and~~to ~~Financial~~a ~~Condition~~Vote of Security Holders.

On ~~May 14~~June 25, 2025, ARS Pharmaceuticals, Inc. (the “Company”) ~~announced~~held its ~~financial~~2025 ~~results~~Annual ~~for~~Meeting of Stockholders (the ~~quarter~~“Annual ~~ended~~Meeting”). ~~March~~As 31of April 28, 2025, inthe record date for the ~~press~~Annual ~~release~~Meeting, ~~attached~~98,210,512 ~~hereto~~shares asof ~~Exhibit~~common ~~99.1~~stock were outstanding and ~~incorporated~~entitled ~~herein~~to vote at the Annual Meeting. A summary of the matters voted upon by ~~reference~~stockholders at the Annual Meeting is set forth below. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest round number.

~~The~~Proposal ~~information in this Item 2.02 of this Current Report on 8-K, including Exhibit 99.~~1,: isElection ~~furnished and shall not be deemed “filed” for purposes~~ of ~~Section~~Directors 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

~~Item~~The ~~9.01~~Company’s ~~Financial~~stockholders ~~Statements~~elected the four persons listed below as Class II directors, each to serve until the Company’s 2028 Annual Meeting of Stockholders, and ~~Exhibits~~until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal. The final voting results are as follows:

(d)


Name of Director Elected	Votes For		Votes Withheld		Broker Non-Votes
Richard Lowenthal, M.S., MSEL		64,911,098		3,015,787		9,563,130
Peter Kolchinsky, Ph.D.		55,848,125		12,078,760		9,563,130
Brenton L. Saunders		56,161,307		11,765,578		9,563,130
Peter A. Thompson, M.D.		61,822,896		6,103,989		9,563,130

ExhibitNumber		Description
99.1		Press Release dated May 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results are as follows:


Votes For	Votes Against		Abstentions		Broker Non-Votes
77,258,380		162,857		68,778		0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ARS PHARMACEUTICALS, INC.
Date: June 26, 2025			ARS Pharmaceuticals, Inc.
Date: May 14, 2025	By:	/s/ Richard Lowenthal, M.S., MSEL
			By:	/s/ Richard Lowenthal
		Richard Lowenthal, M.S., MSEL
			Name:	Richard Lowenthal, M.S., MSEL
		President and Chief Executive Officer
			Title:	President and Chief Executive Officer
		(Principal Executive Officer)

Filing Compare · ARS Pharmaceuticals, Inc.